Paper16613323
Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.
Aishima S and 6 others. Hum Pathol, 2006. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma. Papers, record 16613323. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16613323
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Bile Duct Neoplasms | Major topic |
| Bile Ducts, Intrahepatic | Major topic |
| Carcinoma, Hepatocellular | Major topic |
| Cholangiocarcinoma | Major topic |
| Liver Neoplasms | Major topic |
| Sarcoma | Major topic |
| Adult | |
| Aged | |
| Biomarkers, Tumor | |
| Disease-Free Survival | |
| Female | |
| Humans | |
| Immunoenzyme Techniques | |
| Male | |
| Middle Aged | |
| Neoplasms, Multiple Primary | |
| Prognosis | |
| Survival Rate |
Source PubMed
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42374279 | MRI findings of intrahepatic cholangiocarcinoma with sarcomatoid differentiation: a retrospective case series. | BMC Med Imaging | 2026 | https://conductscience.org/library/papers/42374279 | PubMed |
| 42226136 | Combining preoperative clinical and ultrasound radiomic features to predict the predominant component of combined hepatocellular carcinoma-cholangiocarcinoma. | BMC Gastroenterol | 2026 | https://conductscience.org/library/papers/42226136 | PubMed |
| 38024583 | Pathologic features and clinical treatment of sarcomatoid intrahepatic cholangiocarcinoma. | Intractable Rare Dis Res | 2023 | https://conductscience.org/library/papers/38024583 | PubMed |
| 30774275 | Analysis of intrahepatic sarcomatoid cholangiocarcinoma: Experience from 11 cases within 17 years. | World J Gastroenterol | 2019 | https://conductscience.org/library/papers/30774275 | PubMed |
| 30314525 | Imaging and clinical features of primary hepatic sarcomatous carcinoma. | Cancer Imaging | 2018 | https://conductscience.org/library/papers/30314525 | PubMed |
| 30191007 | Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress. | Hepat Oncol | 2015 | https://conductscience.org/library/papers/30191007 | PubMed |
| 29879137 | The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. | PLoS One | 2018 | https://conductscience.org/library/papers/29879137 | PubMed |
| 29856900 | Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. | Cancer Sci | 2018 | https://conductscience.org/library/papers/29856900 | PubMed |
| 29667093 | The Predictive Value of Staging Systems and Inflammation Scores for Patients with Combined Hepatocellular Cholangiocarcinoma After Surgical Resection: a Retrospective Study. | J Gastrointest Surg | 2018 | https://conductscience.org/library/papers/29667093 | PubMed |
| 29619266 | Intrahepatic Sarcomatous Cholangiocarcinoma: Case Report and Review of the Literature. | Case Rep Surg | 2018 | https://conductscience.org/library/papers/29619266 | PubMed |
| 27552844 | Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. | Chin J Cancer | 2016 | https://conductscience.org/library/papers/27552844 | PubMed |
| 27161394 | Immunohistochemical study of hepatocyte, cholangiocyte and stem cell markers of hepatocellular carcinoma: the second report: relationship with tumor size and cell differentiation. | J Hepatobiliary Pancreat Sci | 2016 | https://conductscience.org/library/papers/27161394 | PubMed |
| 25253966 | Risk factors for combined hepatocellular-cholangiocarcinoma: a hospital-based case-control study. | World J Gastroenterol | 2014 | https://conductscience.org/library/papers/25253966 | PubMed |
| 21333016 | Genome-wide expression patterns associated with oncogenesis and sarcomatous transdifferentation of cholangiocarcinoma. | BMC Cancer | 2011 | https://conductscience.org/library/papers/21333016 | PubMed |
| 20454704 | Intrahepatic sarcomatoid cholangiocarcinoma. | J Oncol | 2010 | https://conductscience.org/library/papers/20454704 | PubMed |
| 19763713 | Combined hepatocellular and cholangiocarcinoma with sarcomatoid transformation: radiologic-pathologic correlation of a case. | Hepatol Int | 2009 | https://conductscience.org/library/papers/19763713 | PubMed |
| 17072946 | Hepatic progenitor cells in human liver tumor development. | World J Gastroenterol | 2006 | https://conductscience.org/library/papers/17072946 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16613323
GET https://conductscience.org/api/papers/v1/16613323/authors